PVLA
NASDAQ · Biotechnology
Palvella Therapeutics Inc
$150.56
-3.76 (-2.44%)
Open$154.72
Previous Close$154.32
Day High$154.72
Day Low$149.20
52W High$161.38
52W Low$54.48
Volume—
Avg Volume195.4K
Market Cap2.22B
P/E Ratio—
EPS$-4.82
SectorBiotechnology
Analyst Ratings
Strong Buy
22 analysts
Price Target
-64.9% upside
Current
$150.56
$150.56
Target
$52.81
$52.81
$42.56
$52.81 avg
$76.13
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 557.30M | 491.27M | 158.95M |
| Net Income | -111,744,018 | -88,654,457 | 26.26M |
| Profit Margin | -57.3% | -54.5% | 16.5% |
| EBITDA | -92,024,313 | -77,065,494 | 46.23M |
| Free Cash Flow | — | — | 10.92M |
| Rev Growth | +13.4% | +13.4% | +20.5% |
| Debt/Equity | 0.63 | 0.63 | 0.49 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $265.21 | +0.28% | 74.0 | 466.74B |
| AMGN | Amgen Inc | $410.24 | +4.34% | 23.7 | 207.25B |
| GILD | Gilead Sciences Inc | $152.67 | +1.40% | — | 187.10B |
| VRTX | Vertex Pharmaceuticals Inc | $514.99 | +0.84% | 29.7 | 130.64B |
| REGN | Regeneron Pharmaceuticals | $803.90 | +0.72% | 18.6 | 80.58B |
| ALNY | Alnylam Pharmaceuticals Inc | $251.65 | +3.00% | 40.0 | 32.33B |